Summary of most relevant clinical studies on T-PLL
| Regimen . | Trial . | Disease status . | n . | ORR, % . | CR, % . | PR, % . | PFS, mo . | OSa, mo . | Reference . |
|---|---|---|---|---|---|---|---|---|---|
| Pentostatin | Single center, retrospective | Pretreated | 56 | 45 | 9 | 36 | 6 | 9 | 55 |
| Alemtuzumab, IV | Single center, retrospective | Pretreated | 15 | 73 | 60 | 13 | 6 | 8 | 46 |
| Alemtuzumab, IV | Multicenter, prospective | Pretreated | 39 | 76 | 60 | 16 | 7 | 10 | 47 |
| Alemtuzumab, IV | Multicenter, retrospective | Untreated | 4 | 75 | 75 | 0 | 4.5 | 7.5 | 52 |
| Pretreated | 72 | 50 | 37.5 | 12.5 | |||||
| Pentostatin + alemtuzumab, IV | Single center, prospective | Pretreated | 13 | 69 | 62 | 8 | 7.8 | 10.2 | 56 |
| Alemtuzumab, IV | Single center, prospective | Untreated | 32 | 91 | 81 | 10 | (67%) 12 mo | (37%) 48 mo | 4 |
| Alemtuzumab, sc | Untreated | 9 | 33 | 33 | 0 | (67%) 12 mo | (33%) 48 mo | ||
| Alemtuzumab, IV | Pretreated | 45 | 74 | 60 | 14 | (26%) 12 mo | (18%) 48 mo | ||
| FMC + alemtuzumab, IV | Multicenter, prospective | Untreated | 16 | 92 | 48 | 44 | 11.5 | 17.1 | 5 |
| Pretreated | 9 | ||||||||
| Bendamustine | Multicenter, retrospective | Untreated | 6 | 55.3 | 20 | 33.3 | 5 | 8.7 | 7 |
| Pretreated | 9 | ||||||||
| Alemtuzumab, IV | Single center, retrospective | Untreated | 42 | 81 | 61 | 20 | 11 | 15 | 15 |
| Alemtuzumab, IV + pentostatin | Untreated | 13 | 82 | 73 | 9 | 4.3 | 10.4 | ||
| Alemtuzumab, IV | Pretreated | 15 | 46 | 46 | — | 3 | 15 | ||
| Alemtuzumab, IV + pentostatin | Pretreated | 5 | 75 | 50 | 25 | 2.6 | 2.6 | ||
| FMC + alemtuzumab, sc | Multicenter, prospective | Untreated | 13 | 68.7 | 25.8% CR, 6.25% CRi | 36.6 | 7.5 | 11.5 | 8 |
| Pretreated | 5 |
| Regimen . | Trial . | Disease status . | n . | ORR, % . | CR, % . | PR, % . | PFS, mo . | OSa, mo . | Reference . |
|---|---|---|---|---|---|---|---|---|---|
| Pentostatin | Single center, retrospective | Pretreated | 56 | 45 | 9 | 36 | 6 | 9 | 55 |
| Alemtuzumab, IV | Single center, retrospective | Pretreated | 15 | 73 | 60 | 13 | 6 | 8 | 46 |
| Alemtuzumab, IV | Multicenter, prospective | Pretreated | 39 | 76 | 60 | 16 | 7 | 10 | 47 |
| Alemtuzumab, IV | Multicenter, retrospective | Untreated | 4 | 75 | 75 | 0 | 4.5 | 7.5 | 52 |
| Pretreated | 72 | 50 | 37.5 | 12.5 | |||||
| Pentostatin + alemtuzumab, IV | Single center, prospective | Pretreated | 13 | 69 | 62 | 8 | 7.8 | 10.2 | 56 |
| Alemtuzumab, IV | Single center, prospective | Untreated | 32 | 91 | 81 | 10 | (67%) 12 mo | (37%) 48 mo | 4 |
| Alemtuzumab, sc | Untreated | 9 | 33 | 33 | 0 | (67%) 12 mo | (33%) 48 mo | ||
| Alemtuzumab, IV | Pretreated | 45 | 74 | 60 | 14 | (26%) 12 mo | (18%) 48 mo | ||
| FMC + alemtuzumab, IV | Multicenter, prospective | Untreated | 16 | 92 | 48 | 44 | 11.5 | 17.1 | 5 |
| Pretreated | 9 | ||||||||
| Bendamustine | Multicenter, retrospective | Untreated | 6 | 55.3 | 20 | 33.3 | 5 | 8.7 | 7 |
| Pretreated | 9 | ||||||||
| Alemtuzumab, IV | Single center, retrospective | Untreated | 42 | 81 | 61 | 20 | 11 | 15 | 15 |
| Alemtuzumab, IV + pentostatin | Untreated | 13 | 82 | 73 | 9 | 4.3 | 10.4 | ||
| Alemtuzumab, IV | Pretreated | 15 | 46 | 46 | — | 3 | 15 | ||
| Alemtuzumab, IV + pentostatin | Pretreated | 5 | 75 | 50 | 25 | 2.6 | 2.6 | ||
| FMC + alemtuzumab, sc | Multicenter, prospective | Untreated | 13 | 68.7 | 25.8% CR, 6.25% CRi | 36.6 | 7.5 | 11.5 | 8 |
| Pretreated | 5 |
sc, subcutaneous.